|
1
|
Arnold M, Abnet CC, Neale RE, Vignat J,
Giovannucci EL, McGlynn KA and Bray F: Global burden of 5 major
types of gastrointestinal cancer. Gastroenterology.
159:335–349.e15. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al: Global surveillance of cancer survival 1995–2009: Analysis
of individual data for 25,676,887 patients from 279
population-based registries in 67 countries (CONCORD-2). Lancet.
385:977–1010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shuchai Z, Changliang S, Wenbing S,
Jingwei S, Juan L and Zhikun L: Prognostic factors of patients with
esophageal cancer after radical resection. Chin J Oncol.
34:281–286. 2012.
|
|
4
|
GBD 2017 Stomach Cancer Collaborators, .
The global, regional, and national burden of stomach cancer in 195
countries, 1990–2017: A systematic analysis for the global burden
of disease study 2017. Lancet Gastroenterol Hepatol. 5:42–54. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E,
Yan T, Lu X, Huang F, Kong P, et al: Whole-genome sequencing of 508
patients identifies key molecular features associated with poor
prognosis in esophageal squamous cell carcinoma. Cell Res.
12–May;2020.(Epub ahead of print). View Article : Google Scholar
|
|
6
|
Samur MK: RTCGAToolbox: A new tool for
exporting TCGA Firehose data. PLoS One. 9:e1063972014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Su H, Hu N, Yang HH, Wang C, Takikita M,
Wang QH, Giffen C, Clifford R, Hewitt SM, Shou JZ, et al: Global
Gene expression profiling and validation in esophageal squamous
cell carcinoma and its association with clinical phenotypes. Clin
Cancer Res. 17:2955–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu N, Clifford RJ, Yang HH, Wang C,
Goldstein AM, Ding T, Taylor PR and Lee MP: Genome wide analysis of
DNA copy number neutral loss of heterozygosity (CNNLOH) and its
relation to gene expression in esophageal squamous cell carcinoma.
BMC Genomics. 11:5762010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu K, Ganesan K, Tan LK, Laban M, Wu J,
Zhao XD, Li H, Leung CH, Zhu Y, Wei CL, et al: A precisely
regulated gene expression cassette potently modulates metastasis
and survival in multiple solid cancers. PLoS Genet. 4:e10001292008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gene Ontology Consortium: The Gene
Ontology (GO) project in 2006. Nucleic Acids Res. 34((Database
Issue)): D322–D326. 2005.
|
|
11
|
Minoru K and Susumu G: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47:D607–D613. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kohl M, Wiese S and Warscheid B:
Cytoscape: Software for visualization and analysis of biological
networks. Methods Mol Biol. 696:291–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1,287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Michaylira CZ, Wong GS, Miller CG,
Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim
SB, Herlyn M, et al: Periostin, a cell adhesion molecule,
facilitates invasion in the tumor microenvironment and annotates a
novel tumor-invasive signature in esophageal cancer. Cancer Res.
70:5281–5292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng W, Wang Y, Liu Z, Cheng H and Xue Y:
HemI: A toolkit for illustrating heatmaps. PLoS One. 9:e1119882014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cools-Lartigue J, Spicer J and Ferri LE:
Current status of management of malignant disease: Current
management of esophageal cancer. J Gastrointest Surg. 19:964–972.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li B, Li J, Xu WW, Guan XY, Qin YR, Zhang
LY, Law S, Tsao SW and Cheung AL: Suppression of esophageal tumor
growth and chemoresistance by directly targeting the PI3K/AKT
pathway. Oncotarget. 5:11576–11587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Gao Q, Guo L and Lu SH: The
PTEN/PI3K/Akt pathway regulates stem-like cells in primary
esophageal carcinoma cells. Cancer Biol Ther. 11:950–958. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hao Z, Zhang H and Cowell J:
Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in
tumorigenesis, and potential as a biomarker. Tumour Biol.
33:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xie C, Powell C, Yao M, Wu J and Dong Q:
Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int
J Biochem Cell Biol. 47:113–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Loussouarn D, Campion L, Leclair F,
Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R and
Jézéquel P: Validation of UBE2C protein as a prognostic marker in
node-positive breast cancer. Br J Cancer. 101:166–173. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takahashi Y, Ishii Y, Nishida Y, Ikarashi
M, Nagata T, Nakamura T, Yamamori S and Asai S: Detection of
aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in
advanced colon cancer with liver metastases by DNA microarray and
two-color FISH. Cancer Genet Cytogenet. 168:30–35. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Palumbo A Jr, Da Costa NM, De Martino M,
Sepe R, Pellecchia S, de Sousa VP, Nicolau Neto P, Kruel CD,
Bergman A, Nasciutti LE, et al: UBE2C is overexpressed in ESCC
tissues and its abrogation attenuates the malignant phenotype of
ESCC cell lines. Oncotarget. 7:65876–65887. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li L, Li X, Wang W, Gao T and Shi Z: UBE2C
is involved in the functions of ECRG4 on esophageal squamous cell
carcinoma. Biomed Pharmacother. 98:201–206. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Demetrick DJ, Matsumoto S, Hannon GJ,
Okamoto K, Xiong Y, Zhang H and Beach DH: Chromosomal mapping of
the genes for the human cell cycle proteins cyclin C (CCNC), cyclin
E (CCNE), p21 (CDKN1) and KAP (CDKN3). Cytogenet Cell Genet.
69:190–192. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nalepa G, BarnholtzSloan J, Enzor R, Dey
D, He Y, Gehlhausen JR, Lehmann AS, Park SJ, Yang Y, Yang X, et al:
The tumor suppressor CDKN3 controls mitosis. J Cell Biol.
201:997–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cress WD, Yu P and Wu J: Expression and
alternative splicing of the cyclin-dependent kinase inhibitor-3
gene in human cancer. Int J Biochem Cell Biol. 91:98–101. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li T, Xue H, Guo Y and Guo K: CDKN3 is an
independent prognostic factor and promotes ovarian carcinoma cell
proliferation in ovarian cancer. Oncol Rep. 31:1825–1831. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jaime B, Ana María E and Ingrid M:
Targeting CDKN3 in cervical cancer. Expert Opin Ther Targets.
18:1149–1162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fan C, Chen L, Huang Q, Shen T, Welsh EA,
Teer JK, Cai J, Cress WD and Wu J: Overexpression of major CDKN3
transcripts is associated with poor survival in lung
adenocarcinoma. Br J Cancer. 113:1735–1743. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Q, Chen K, Guo G, Li F, Chen C, Wang
S, Nalepa G, Huang S and Chen JL: A critical role of CDKN3 in
Bcr-Abl-mediated tumorigenesis. PLoS One. 9:e1116112014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Martinsson-Ahlzen HS, Liberal V,
Grunenfelder B, Chaves SR, Spruck CH and Reed SI: Cyclin-dependent
kinase-associated proteins Cks1 and Cks2 are essential during early
embryogenesis and for cell cycle progression in somatic cells. Mol
Cell Biol. 28:5698–5709. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rother K, Dengl M, Lorenz J, Tschöp K,
Kirschner R, Mössner J and Engeland K: Gene expression of
cycli-dependent kinase subunit Cks2 is repressed by the tumor
suppressor p53 but not by the related proteins p63 or p73. FEBS
Lett. 581:1166–1172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lv M, Zhang X, Li M, Chen Q, Ye M, Liang
W, Ding L, Cai H, Fu D and Lv Z: miR-26a and its target CKS2
modulate cell growth and tumorigenesis of papillary thyroid
carcinoma. PLoS One. 8:e675912013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hua K, Jin J, Zhang H, Zhao B, Wu C, Xu H
and Fang L: MicroRNA-7 inhibits proliferation, migration and
invasion of thyroid papillary cancer cells via targeting CKS2. Int
J Oncol. 49:1531–1540. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto
K, Tsujimoto M and Bay BH: Y-box binding protein 1 is up-regulated
in proliferative breast cancer and its inhibition deregulates the
cell cycle. Int J Oncol. 37:483–492. 2010.PubMed/NCBI
|
|
42
|
Wang JJ, Fang ZX, Ye HM, You P, Cai MJ,
Duan HB, Wang F and Zhang ZY: Clinical significance of
overexpressed cyclin-dependent kinase subunits 1 and 2 in
esophageal carcinoma. Dis Esophagus. 26:729–736. 2013.PubMed/NCBI
|
|
43
|
Kita Y, Nishizono Y, Okumura H, Uchikado
Y, Sasaki K, Matsumoto M, Setoyama T, Tanoue K, Omoto I, Mori S, et
al: Clinical and biological impact of cyclin-dependent kinase
subunit 2 in esophageal squamous cell carcinoma. Oncol Rep.
31:1986–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Taniuchi K, Nakagawa H, Nakamura T, Eguchi
H, Ohigashi H, Ishikawa O, Katagiri T and Nakamura Y:
Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with
membrane trafficking of discs large homologue 5, can attenuate
growth of pancreatic cancer cell. Cancer Res. 65:105–112.
2005.PubMed/NCBI
|
|
45
|
Stangel D, Erkan M, Buchholz M, Gress T,
Michalski C, Raulefs S, Friess H and Kleeff J: Kif20a inhibition
reduces migration and invasion of pancreatic cancer cells. J Surg
Res. 197:91–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang W, He W, Shi Y, Gu H, Li M, Liu Z,
Feng Y, Zheng N, Xie C and Zhang Y: High Expression of KIF20A is
associated with poor overall survival and tumor progression in
early-stage cervical squamous cell carcinoma. PLoS One.
11:e01674492016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jia D, Wei H and Shi H: Positive
expression of KIF20A indicates poor prognosis of glioma patients.
Onco Targets Ther. 9:6741–6749. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bobustuc GC, Kassam AB, Rovin RA, Jeudy S,
Smith JS, Isley B, Singh M, Paranjpe A, Srivenugopal KS and Konduri
SD: MGMT inhibition in ER positive breast cancer leads to CDC2,
TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ERα
and survivin inhibition and enhances response to temozolomide.
Oncotarget. 9:29727–29742. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Suzuki N, Hazama S, Ueno T, Matsui H,
Shindo Y, Iida M, Yoshimura K, Yoshino S, Takeda K and Oka M: A
phase I clinical trial of vaccination with KIF20A-derived peptide
in combination with gemcitabine for patients with advanced
pancreatic cancer. J Immunother. 37:36–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Asahara S, Takeda K, Yamao K, Maguchi H
and Yamaue H: Phase I/II clinical trial using HLA-A24-restricted
peptide vaccine derived from KIF20A for patients with advanced
pancreatic cancer. J Transl Med. 11:2912013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Saito K, Ohta S, Kawakami Y, Yoshida K and
Toda M: Functional analysis of KIF20A, a potential
immunotherapeutic target for glioma. J Neurooncol. 132:63–74. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Modesti M, Budzowska M, Baldeyron C,
Demmers JA, Ghirlando R and Kanaar R: RAD51AP1 is a
structure-specific DNA binding protein that stimulates joint
molecule formation during RAD51-mediated homologous recombination.
Mol Cell. 28:468–481. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dunlop MH, Dray E, Zhao W, San Filippo J,
Tsai MS, Leung SG, Schild D, Wiese C and Sung P: Mechanistic
insights into RAD51-associated protein 1 (RAD51AP1) action in
homologous DNA repair. J Biol Chem. 287:12343–12347. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Obama K, Satoh S, Hamamoto R, Sakai Y,
Nakamura Y and Furukawa Y: Enhanced expression of RAD51 associating
protein-1 is involved in the growth of intrahepatic
cholangiocarcinoma cells. Clin Cancer Res. 14:1333–1339. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kauffmann A, Rosselli F, Lazar V,
Winnepenninckx V, Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz
A and Sarasin A: High expression of DNA repair pathways is
associated with metastasis in melanoma patients. Oncogene.
27:565–573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J,
Adamson E, Mercola D and McClelland M: Survey of differentially
methylated promoters in prostate cancer cell lines. Neoplasia.
7(748): IN1–IN7. 2005.
|
